11.07.18
Evonik increased adjusted EBITDA to €692 million in the third quarter of 2018 (prior-year: €640 million). The two growth segments – Nutrition & Care and Resource Efficiency – contributed considerable earnings growth, helping to increase profitability. The adjusted EBITDA margin improved to 18.2% compared with 18.0% in the same quarter of the previous year.
Sales increased to €3.8 billion in the third quarter (prior-year: €3.6 billion), largely due to higher selling prices. Adjusted net income rose 35% to €370 million, which corresponds to adjusted earnings per share of €0.79.
“We are consistently implementing our strategy,” said Christian Kullmann, chairman of the Executive Board. “We will continue to actively shape our portfolio, bring innovations to the market and drive cultural change.”
Evonik confirms its outlook, which it had raised after the first half of the year, for the fiscal year 2018 and is still expecting an adjusted EBITDA between €2.60 and €2.65 billion and sales to increase slightly (previous year: €14.4 billion). Evonik is sticking to its outlook for a noticeably higher free cash flow for 2018 compared to the prior year (€511 million).
Sales increased to €3.8 billion in the third quarter (prior-year: €3.6 billion), largely due to higher selling prices. Adjusted net income rose 35% to €370 million, which corresponds to adjusted earnings per share of €0.79.
“We are consistently implementing our strategy,” said Christian Kullmann, chairman of the Executive Board. “We will continue to actively shape our portfolio, bring innovations to the market and drive cultural change.”
Evonik confirms its outlook, which it had raised after the first half of the year, for the fiscal year 2018 and is still expecting an adjusted EBITDA between €2.60 and €2.65 billion and sales to increase slightly (previous year: €14.4 billion). Evonik is sticking to its outlook for a noticeably higher free cash flow for 2018 compared to the prior year (€511 million).
